Clinical Trials Logo

Neuroectodermal Tumors clinical trials

View clinical trials related to Neuroectodermal Tumors.

Filter by:

NCT ID: NCT00070109 Completed - Clinical trials for Recurrent Childhood Rhabdomyosarcoma

Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors

Start date: January 2008
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well trabectedin works in treating young patients with recurrent or refractory soft tissue sarcoma or Ewing's family of tumors. Drugs used in chemotherapy such as trabectedin use different ways to stop tumor cells from dividing so they stop growing or die.

NCT ID: NCT00063973 Completed - Clinical trials for Recurrent Childhood Ependymoma

Cilengitide in Treating Children With Refractory Primary Brain Tumors

Start date: July 2003
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of cilengitide in treating children with recurrent, progressive, or refractory primary CNS tumors. Cilengitide may slow the growth of brain cancer cells by stopping blood flow to the tumor.

NCT ID: NCT00055952 Completed - Sarcoma Clinical Trials

Exatecan Mesylate in Treating Patients With Ewing's Sarcoma, Primitive Neuroectodermal Tumor, or Desmoplastic Small Round Cell Tumor

Start date: January 2003
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of exatecan mesylate in treating patients who have relapsed or refractory Ewing's sarcoma or peripheral primitive neuroectodermal tumor or desmoplastic small round cell tumor.

NCT ID: NCT00053963 Completed - Clinical trials for Refractory Chronic Lymphocytic Leukemia

FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia

Start date: September 2002
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of FR901228 in treating children with refractory or recurrent solid tumors or leukemia. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die

NCT ID: NCT00052780 Completed - Clinical trials for Recurrent Childhood Ependymoma

Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors

Start date: October 2002
Phase: Phase 1
Study type: Interventional

Phase I trial to study the safety of combining O6-benzylguanine with temozolomide in treating children who have recurrent or refractory brain tumors. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. O6-benzylguanine may increase the effectiveness of temozolomide by making tumor cells more sensitive to the drug.

NCT ID: NCT00048984 Completed - Clinical trials for Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor

Diagnostic Study of Tumor Characteristics in Patients With Ewing's Sarcoma

Start date: January 2003
Phase: N/A
Study type: Observational

Diagnostic trial to study genetic differences in patients who have Ewing's sarcoma. Genetic testing may help predict how cancer will respond to treatment and allow doctors to plan more effective therapy.

NCT ID: NCT00047177 Completed - Clinical trials for Brain and Central Nervous System Tumors

Oxaliplatin in Treating Children With Recurrent or Refractory Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor

Start date: October 2002
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of oxaliplatin in treating children who have recurrent or refractory medulloblastoma, supratentorial primitive neuroectodermal or atypical teratoid rhabdoid tumor.

NCT ID: NCT00030667 Completed - Clinical trials for Gastrointestinal Stromal Tumor

Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood

Start date: May 2002
Phase: Phase 2
Study type: Interventional

Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have relapsed or refractory solid tumors of childhood. Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for their growth.

NCT ID: NCT00025077 Completed - Clinical trials for Brain and Central Nervous System Tumors

Combination Chemotherapy, Surgery or Radiation Therapy, and Peripheral Stem Cell Transplant in Treating Patients With Recurrent Medulloblastoma or Primitive Neuroectodermal and Pineal Tumors

Start date: January 2000
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving a chemotherapy drug before surgery or radiation therapy may shrink the tumor so that it can be removed during surgery or radiation therapy. Peripheral stem cell transplant may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy and allow doctors to give higher doses of chemotherapy. PURPOSE: This phase II trial is studying how well combination chemotherapy followed by surgery or radiation therapy and peripheral stem cell transplant work in treating patients with recurrent medulloblastoma or primitive neuroectodermal and pineal tumors.

NCT ID: NCT00019578 Completed - Brain Metastases Clinical Trials

Stereotactic Radiosurgery in Treating Patients With Brain Tumors

Start date: November 1998
Phase: Phase 1
Study type: Interventional

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. PURPOSE: Phase I trial to study the effectiveness of stereotactic radiosurgery in treating patients who have brain tumors.